RUNX2 and CD4+/CD56+ hematodermic neoplasm: Since the super-enhancer of RUNX2 appeared to promote the development of BPDCN by activating the expression of MYC and RUNX2, we examined whether the BRD4 inhibitor JQ1 abrogated the proliferation of CAL-1 cells in vitro.